Electric field therapy combined with chemo shows promise for tough pancreatic cancer

NCT ID NCT06390059

Completed Disease control Sponsor: NovoCure Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatment. The goal was to see if the combination is safe and can control the disease. Participants wore the device at home for at least 18 hours a day. The study is now complete, and results will show how well the treatment worked at stopping tumor growth and improving survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor Treating Fields (TTFields) device plus atezolizumab, gemcitabine, and nab-paclitaxel
What this could lead to: If successful, this combination could offer a new first-line treatment option to help control metastatic pancreatic cancer and potentially extend survival.
What could go wrong: This is a small, single-arm pilot study without a comparison group, so results may not be definitive. The treatment involves multiple drugs and a wearable device, which may cause side effects or be difficult to tolerate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Asklepios Hospital Altona

Hamburg, 22763, Germany
Clara Campal Comprehensive Cancer Center (CIOCC)

Madrid, 28050, Spain
Fribourg Cantonal Hospital, Internal Medicine and Oncology

Fribourg, 1708, Switzerland
Inselspital, University Hospital Bern

Bern, 3010, Switzerland
Regional University Hospital of Malaga

Málaga, 29010, Spain
University Clinic of Navarra - Pamplona

Pamplona, 31008, Spain
University General Hospital Gregorio Maranon

Madrid, 28007, Spain
University Hospital Bulovka

Prague, 180 81, Czechia
University Hospital Foundation Jimenez Diaz

Madrid, 28040, Spain
University Hospital Hradec Kralove

Hradec Králové, 500 05, Czechia
University Hospital Motol

Prague, 150 06, Czechia
University Hospital Olomouc

Olomouc, 779 00, Czechia
University Hospital Tuebingen

Tübingen, 72076, Germany
University Hospital Ulm

Ulm, 89081, Germany
University Hospital Vall d'Hebron

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.